ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Piet G. M. Jansen
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Velthuis, H. t.
Right arrow Articles by Wildevuur, C. R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Velthuis, H. t.
Right arrow Articles by Wildevuur, C. R. H.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1996;61:1153-1157
© 1996 The Society of Thoracic Surgeons

Original Article: Cardiovascular

Specific Complement Inhibition With Heparin-Coated Extracorporeal Circuits

Henk te Velthuis, PhD, Piet G. M. Jansen, MDPhD, C. Erik Hack, MDPhD, León Eijsman, MDPhD, Charles R. H. Wildevuur, MDPhD

Centre for Cardiopulmonary Surgery Amsterdam, Department of Cardiac Surgery, Academical Hospital Vrije Universiteit, and Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, the Netherlands

Accepted for publication November 6, 1995.

Background. Although it is well established that heparin-coated extracorporeal circuits reduce complement activation during cardiac operations, little in vivo information is available on the reduction in alternative and classic pathway activation.

Methods. In a prospective, randomized study involving patients undergoing coronary artery bypass grafting with standard full heparinization, we compared heparin-coated circuits (Duraflo II) (10 patients) with uncoated circuits (10 patients) and assessed the extent of initiation of complement activation by detecting iC3 (C3b-like C3) concentrations, classic pathway activation by C4b/c (C4b, iC4b, C4c) concentrations, terminal pathway activation by soluble C5b-9 concentrations, and C3 activation by C3a (C3a desArg) and C3b/c (C3b, iC3b, C3c) concentrations.

Results. Heparin-coated extracorporeal circuits significantly reduced circulating complement activation product C3b/c and soluble C5b-9 concentrations at the end of cardiopulmonary bypass and after protamine sulfate administration compared with the uncoated circuits, but not iC3, C4b/c, or C3a concentrations.

Conclusions. Heparin-coated extracorporeal circuits reduce complement activation through the alternative complement pathway, probably at the C3 convertase level, and, consequently, the terminal pathway. C3b/c seems to be a more sensitive marker than C3a to assess complement activation during cardiac operations.


Related Article

Invited Commentary

Ann. Thorac. Surg. 61: 1157-1157. [Full Text]



This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou
Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes
Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
E. Khoshbin, A. E. Dux, H. Killer, A. W Sosnowski, R. K Firmin, and G. J Peek
A comparison of radiographic signs of pulmonary inflammation during ECMO between silicon and poly-methyl pentene oxygenators
Perfusion, January 1, 2007; 22(1): 15 - 21.
[Abstract] [PDF]

Home page
 PerfusionHome page
E. Khoshbin, C. Westrope, S. Pooboni, D. Machin, H. Killer, G. J Peek, A. W Sosnowski, and R. K Firmin
Performance of polymethyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicone membrane oxygenators
Perfusion, May 1, 2005; 20(3): 129 - 134.
[Abstract] [PDF]

Home page
 Journal of Bioactive and Compatible PolymersHome page
U. Demirkilic, E. Kuralay, H. Tatar, M. Kocakulak, C. Kocum, and H. Ayhan
Investigation of Blood Compatibility and Determination of Clinical Performance of PMEA Coated and Flow Optimized Oxygenator
Journal of Bioactive and Compatible Polymers, September 1, 2004; 19(5): 395 - 408.
[Abstract] [PDF]

Home page
 CVIHome page
S. Zeerleder, C. Caliezi, G. van Mierlo, A. Eerenberg-Belmer, I. Sulzer, C. E. Hack, and W. A. Wuillemin
Administration of C1 Inhibitor Reduces Neutrophil Activation in Patients with Sepsis
Clin. Vaccine Immunol., July 1, 2003; 10(4): 529 - 535.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. M. Palatianos, C. N. Foroulis, M. I. Vassili, G. Astras, K. Triantafillou, E. Papadakis, A. A. Lidoriki, E. Iliopoulou, and E. N. Melissari
A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit
Ann. Thorac. Surg., July 1, 2003; 76(1): 129 - 135.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
P. Borgdorff, R. H. van den Berg, M. A. Vis, G. C. van den Bos, and G. J. Tangelder
PUMP-INDUCED PLATELET AGGREGATION IN ALBUMIN-COATED EXTRACORPOREAL SYSTEMS
J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 946 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
H. P. Wendel and G. Ziemer
Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation
Eur. J. Cardiothorac. Surg., September 1, 1999; 16(3): 342 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. M. McCarthy, J.-P. P. Yared, R. C. Foster, D. A. Ogella, J. A. Borsh, and D. M. Cosgrove III
A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations
Ann. Thorac. Surg., May 1, 1999; 67(5): 1268 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
V. Videm, T. E. Mollnes, K. Bergh, E. Fosse, B. Mohr, T.-A. Hagve, A. O. Aasen, and J. L. Svennevig
HEPARIN-COATED CARDIOPULMONARY BYPASS EQUIPMENT. II. MECHANISMS FOR REDUCED COMPLEMENT ACTIVATION IN VIVO
J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 803 - 809.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
C B. Mahoney
Heparin-bonded circuits: clinical outcomes and costs
Perfusion, May 1, 1998; 13(3): 192 - 204.
[Abstract] [PDF]

Home page
 Pharmacol. Rev.Home page
S. C. Makrides
Therapeutic Inhibition of the Complement System
Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Bruins, H. t. Velthuis, A. P. Yazdanbakhsh, P. G. M. Jansen, F. W. J. van Hardevelt, E. M. F. H. de Beaumont, C. R. H. Wildevuur, L. Eijsman, A. Trouwborst, and C. E. Hack
Activation of the Complement System During and After Cardiopulmonary Bypass Surgery : Postsurgery Activation Involves C-Reactive Protein and Is Associated With Postoperative Arrhythmia
Circulation, November 18, 1997; 96(10): 3542 - 3548.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. t. Velthuis, C. Baufreton, P. G. M. Jansen, C. M. Thijs, C. E. Hack, A. Sturk, C. R. H. Wildevuur, and D. Y. Loisance
HEPARIN COATING OF EXTRACORPOREAL CIRCUITS INHIBITS CONTACT ACTIVATION DURING CARDIAC OPERATIONS
J. Thorac. Cardiovasc. Surg., July 1, 1997; 114(1): 117 - 122.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.